Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-17 |
2024-03 |
-0.1 |
-0.24 |
-0.14 |
-140.00% |
2024-03-14 |
2023-12 |
-0.26 |
-0.44 |
-0.18 |
-69.23% |
2024-03-14 |
2023-12 |
-0.26 |
N/A |
N/A |
N/A |
2023-11-02 |
2023-09 |
-0.24 |
N/A |
N/A |
N/A |
2023-11-02 |
2023-09 |
-0.24 |
-0.26 |
-0.02 |
-8.33% |
2023-08-03 |
2023-06 |
-0.22 |
-0.26 |
-0.04 |
-18.18% |
Date |
Firm |
Action |
From |
To |
2023-08-16 |
Truist Securities |
Upgrade |
Buy |
Buy |
2023-06-04 |
Needham |
Upgrade |
Buy |
Buy |
2023-06-01 |
Needham |
Upgrade |
|
Buy |
2023-05-04 |
Wells Fargo |
Upgrade |
|
Overweight |
2023-05-04 |
Needham |
Upgrade |
|
Buy |
2023-04-27 |
Needham |
Upgrade |
|
Buy |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Syncona Portfolio Ltd |
21.35M |
50.81M |
12.29% |
2023-06-29 |
Blackstone Inc |
20.49M |
48.76M |
11.79% |
2023-06-29 |
Deep Track Capital, Lp |
15.00M |
35.70M |
8.64% |
2023-06-29 |
TFG Asset Management GP Ltd |
12.00M |
28.56M |
6.91% |
2023-06-29 |
Paradigm Biocapital Advisors LP |
9.22M |
21.94M |
5.31% |
2023-06-29 |
Armistice Capital, LLC |
7.26M |
17.29M |
4.18% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-08-30 |
iShares NASDAQ Biotechnology ETF |
838.30K |
2.69M |
0.48% |
2023-07-30 |
Harbor Disruptive Innovation Fund |
176.79K |
571.04K |
0.10% |
2023-06-29 |
JOHCM Funds Tr-Regnan Global Equity Impact Solutions Fd |
75.23K |
179.05K |
0.04% |
2023-07-30 |
Harbor ETF Tr-Harbor Disruptive Innovation ETF |
68.50K |
221.26K |
0.04% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
53.74K |
167.12K |
0.03% |
2023-08-30 |
SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF |
52.39K |
168.16K |
0.03% |